| Martin Jose Arraiz, MD | |
|
6255 Sharlands Ave, Reno, NV 89523-2882 | |
| (775) 245-6117 | |
| (775) 245-6118 |
| Full Name | Martin Jose Arraiz |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 28 Years |
| Location | 6255 Sharlands Ave, Reno, Nevada |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790766798 | NPI | - | NPPES |
| XPY199375 | Other | CA | MEDI-CAL PIN |
| 20-16904 | Medicaid | NV | |
| 250013236 | Other | NV | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 9611 (Nevada) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Martin Jose Arraiz Professional | 4789075706 | 2 |
News Archive
Treatment-free remission may be feasible in many patients with chronic myeloid leukaemia, say researchers who set out clinical and logistical requirements for discontinuing tyrosine kinase inhibitor therapy.
Patients with advanced hepatocellular (or liver) cancer have high mortality rates, with existing drugs demonstrating only a small, but significant survival advantage. By combining a zebrafish model of liver cancer with data from human tumors, researchers from the Icahn School of Medicine at Mount Sinai hope to identify potential genes of interest that can be targeted for new treatments for hepatocellular carcinoma, the most common form of liver cancer to develop from liver cells.
Tetraphase Pharmaceuticals, Inc. today announced that the U.S. Food & Drug Administration has granted Fast Track designations for both the intravenous (IV) and oral formulations of the company's lead antibiotic candidate, eravacycline.
Using nanoparticles designed specifically to produce a bright Raman spectroscopic signal, a team of investigators at the Center for Cancer Nanotechnology Excellence Focused on Therapy Response (Stanford CCNE) has shown that it can produce whole-body images in small animals that can reveal the location of tumors and track how these nanoparticles traffic through the body.
Precision medicine is getting a jump-start from a new national initiative announced in President Obama's State of the Union message. One Georgia family has already experienced its benefits: genomic testing called whole exome sequencing helped Mayo Clinic neurologist Zbigniew Wszolek, M.D., solve a medical mystery that had left a boy with painful, jerking spasms that at times prevented him from walking or talking.
› Verified 3 days ago
| Entity Name | Martin Jose Arraiz Professional |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831865658 PECOS PAC ID: 4789075706 Enrollment ID: O20211230001940 |
News Archive
Treatment-free remission may be feasible in many patients with chronic myeloid leukaemia, say researchers who set out clinical and logistical requirements for discontinuing tyrosine kinase inhibitor therapy.
Patients with advanced hepatocellular (or liver) cancer have high mortality rates, with existing drugs demonstrating only a small, but significant survival advantage. By combining a zebrafish model of liver cancer with data from human tumors, researchers from the Icahn School of Medicine at Mount Sinai hope to identify potential genes of interest that can be targeted for new treatments for hepatocellular carcinoma, the most common form of liver cancer to develop from liver cells.
Tetraphase Pharmaceuticals, Inc. today announced that the U.S. Food & Drug Administration has granted Fast Track designations for both the intravenous (IV) and oral formulations of the company's lead antibiotic candidate, eravacycline.
Using nanoparticles designed specifically to produce a bright Raman spectroscopic signal, a team of investigators at the Center for Cancer Nanotechnology Excellence Focused on Therapy Response (Stanford CCNE) has shown that it can produce whole-body images in small animals that can reveal the location of tumors and track how these nanoparticles traffic through the body.
Precision medicine is getting a jump-start from a new national initiative announced in President Obama's State of the Union message. One Georgia family has already experienced its benefits: genomic testing called whole exome sequencing helped Mayo Clinic neurologist Zbigniew Wszolek, M.D., solve a medical mystery that had left a boy with painful, jerking spasms that at times prevented him from walking or talking.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Martin Jose Arraiz, MD 6255 Sharlands Ave, Reno, NV 89523-2882 Ph: (775) 786-3040 | Martin Jose Arraiz, MD 6255 Sharlands Ave, Reno, NV 89523-2882 Ph: (775) 245-6117 |
News Archive
Treatment-free remission may be feasible in many patients with chronic myeloid leukaemia, say researchers who set out clinical and logistical requirements for discontinuing tyrosine kinase inhibitor therapy.
Patients with advanced hepatocellular (or liver) cancer have high mortality rates, with existing drugs demonstrating only a small, but significant survival advantage. By combining a zebrafish model of liver cancer with data from human tumors, researchers from the Icahn School of Medicine at Mount Sinai hope to identify potential genes of interest that can be targeted for new treatments for hepatocellular carcinoma, the most common form of liver cancer to develop from liver cells.
Tetraphase Pharmaceuticals, Inc. today announced that the U.S. Food & Drug Administration has granted Fast Track designations for both the intravenous (IV) and oral formulations of the company's lead antibiotic candidate, eravacycline.
Using nanoparticles designed specifically to produce a bright Raman spectroscopic signal, a team of investigators at the Center for Cancer Nanotechnology Excellence Focused on Therapy Response (Stanford CCNE) has shown that it can produce whole-body images in small animals that can reveal the location of tumors and track how these nanoparticles traffic through the body.
Precision medicine is getting a jump-start from a new national initiative announced in President Obama's State of the Union message. One Georgia family has already experienced its benefits: genomic testing called whole exome sequencing helped Mayo Clinic neurologist Zbigniew Wszolek, M.D., solve a medical mystery that had left a boy with painful, jerking spasms that at times prevented him from walking or talking.
› Verified 3 days ago
Kristen Anne Smith, Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 1664 N Virginia St, Reno, NV 89557 Phone: 775-327-2182 | |
Mrs. Teresa May Morros, CBIS Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 1325 Airmotive Way, #175r, Reno, NV 89502 Phone: 775-473-1077 | |
Nicholas Patrick Gut, MD Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 1495 Mill St, Reno, NV 89502 Phone: 775-982-5000 Fax: 775-982-8100 | |
Jesson Baumgartner, Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 343 Elm St Ste 202, Reno, NV 89503 Phone: 775-870-1480 Fax: 877-764-6351 | |
Dr. Stephen Brown, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 1540 Fescue Ct, Reno, NV 89509 Phone: 775-391-7780 | |
Mr. George Mars, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 645 Sierra Rose #202, Reno, NV 89511 Phone: 775-825-9990 Fax: 775-827-1161 | |
Dr. Edwin Gary Starr, M.D. Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 403 Hill St Ste 2, Reno, NV 89501 Phone: 775-544-6401 |